Whalesbook
Banks Ne Dikhaayi Solid Performance!
Leading banks ne Q4 ke liye apne financial results release kiye hain aur sabhi kaafi impressive hain. HDFC Bank ka profit 9.1% badh kar ₹19,221 crore ho gaya, jismein net interest income 3.2% upar gaya. ICICI Bank ne bhi 8.5% profit jump report kiya, yani ₹13,701.7 crore, aur unka net interest income 8.4% badha. Sunne mein aaya hai ki Yes Bank ka profit toh 44.7% tezi se ₹1,068 crore tak pahunch gaya, aur income 15.9% upar chali gayi. Banks ki asset quality bhi sudhri hai, gross non-performing assets kam hue hain. Filhaal, HDFC Bank ka P/E 17.3x, ICICI Bank ka 17.1x, aur Yes Bank ka 19.9x chal raha hai. Ye valuations indicate karte hain ki companies badh rahi hain, par abhi ye mature growth phase mein hain.
Pharma Companies Par US FDA Ki Nazar!
Dhyaan rahe, pharmaceutical sector mein kuch challenges hain. Lupin ki New Jersey facility ko US FDA se teen observations mili hain inspection ke baad. Aur Cipla ke Goa facility ko bhi do observations mili hain. Isse future product launches mein der ho sakti hai ya exports par impact pad sakta hai. Par, sab jagah buri khabar nahi hai, Aurobindo Pharma ko ek naye drug suspension ke liye final USFDA approval mil gaya hai. Pharma stocks, jaise Aurobindo Pharma ka P/E 22.0x, Cipla ka 21.2x, aur Lupin ka 22.6x hai, jo industry average (32.46x) ke aas paas hai. Investors ko pata hona chahiye ki regulatory issues se stock price 10-20% tak gir sakta hai.
Infrastructure Sector Mein Project Milte Rahe
Achhi baat ye hai ki infrastructure sector mein kaam chal raha hai. H G Infra Engineering ko Odisha mein ₹1,582.11 crore ka road construction project mila hai National Highways Authority of India se. Wahi, EMS ne UP Jal Nigam (Urban) ke liye do projects jeete hain, jinme se ek ₹143.79 crore ka aur dusra ₹64.8 crore ka hai. Ye projects dikhate hain ki companies ke paas projects ki pipeline mazboot hai.
Aur Kya Chal Raha Hai?
Baaki corporate news mein HDFC Bank aur Mastek ne ₹13 aur ₹16 per share ka dividend recommend kiya hai. Trent board bonus share issue aur rights issue par विचार karegi. Jio Financial Services ka profit 13.9% gir kar ₹272.2 crore ho gaya, jabki revenue 106.5% badha. Network 18 Media & Investments ka operating revenue 9.7% badh kar ₹616 crore hua.
Risks Aur Outlook
Banks toh stable lag rahe hain, par pharma mein regulatory issues aur US mein pricing pressure ek risk hai. Global factors se Indian pharma exports March mein 23% gir gaye the. Banks ke liye, credit growth dheema ho sakta hai. Trent ka P/E 85x se upar hai, jo high valuation risk dikhata hai. Indian pharma industry FY25 mein 9-11% grow hone ki ummeed hai, par in sab cheezon par nazar rakhni padegi.